Adeno-associated viral delivery of a metabolically regulated insulin transgene to hepatocytes

Molecular and Cellular Endocrinology

Volumn 273, Issue 1-2, 2007, Pages 6-15

  Kozlowski, Miroslaw ^a   Olson, Darin E ^b   Rubin, Janet ^c   Lyszkowicz, Dorota ^b   Campbell, Adam ^b   Thulé, Peter M ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

AAV2; Adeno associated virus; Diabetes; Gene therapy; Transcriptional regulation

Indexed keywords

ADENOVIRUS VECTOR; E1A PROTEIN; GLUCOSE; INSULIN;

ADENO ASSOCIATED VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LINEAGE; CELL SPECIFICITY; CELL STRAIN HEPG2; CELL TYPE; CONTROLLED STUDY; DIABETES MELLITUS; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GLUCOSE BLOOD LEVEL; HEPATOMA CELL; LIVER CELL; METABOLIC REGULATION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TRANSGENE; VIRUS RECOMBINANT;

ANIMALS; CELLS, CULTURED; DEPENDOVIRUS; GENE EXPRESSION; GENETIC VECTORS; GLUCOSE; GREEN FLUORESCENT PROTEINS; HELA CELLS; HEPATOCYTES; HUMANS; HYPERGLYCEMIA; INSULIN; MALE; PROMOTER REGIONS (GENETICS); RATS; RATS, SPRAGUE-DAWLEY; STREPTOZOCIN; TIME FACTORS; TRANSDUCTION, GENETIC; TRANSGENES;

EID: 34347327249     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2007.04.011     Document Type: Article

References (52)

1. Auricchio A., Hildinger M., et al. Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. Hum. Gene Ther. 12 1 (2001) 71-76
2. Bartlett J.S., Wilcher R., et al. Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J. Virol. 74 6 (2000) 2777-2785
3. Blackwood L., and Argyle D.J. The activity of the feline thyroglobulin promoter is compromised by flanking adenoviral sequence. Vet. J. 168 1 (2004) 50-59
4. Chen L., Perlick H., et al. Comparison of retroviral and adeno-associated viral vectors designed to express human clotting factor IX. Hum. Gene Ther. 8 2 (1997) 125-135
5. Chen R., Meseck M., et al. Auto-regulated hepatic insulin gene expression in type 1 diabetic rats. Mol. Ther. 3 4 (2001) 584-590
6. Dong H., Altomonte J., et al. Basal insulin gene expression significantly improves conventional insulin therapy in type 1 diabetic rats. Diabetes 51 1 (2002) 130-138
7. Douar A.M., Poulard K., et al. Intracellular trafficking of adeno-associated virus vectors: routing to the late endosomal compartment and proteasome degradation. J. Virol. 75 4 (2001) 1824-1833
8. Dunn J.C.Y., Tompkins R.G., et al. Hepatocytes in collagen sandwich: evidence for transcriptional and translational regulation. J. Cell Biol. 116 (1992) 1043-1053
9. Ferrari F.K., Samulski T., et al. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J. Virol. 70 5 (1996) 3227-3234
10. Fisher K.J., Gao P., et al. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J. Virol. 70 1 (1996) 520-532
11. Flotte T.R., and Carter B.J. Adeno-associated virus vectors for gene therapy. Gene Ther. 2 6 (1995) 357-362
12. Grimm D., Kern A., et al. Novel tools for production and purification of recombinant adenoassociated virus vectors. Hum. Gene Ther. 9 18 (1998) 2745-2760
13. Groskreutz D.J., Sliwkowski M.X., et al. Genetically engineered proinsulin constitutively processed and secreted as mature, active insulin. J. Biol. Chem. 269 (1994) 6241-6245
14. Haberman R., Kroner-Lux G., et al. Production of adeno-associated viral vectors. In: Dracopoli N., Haines J., Korf B., et al. (Eds). Current Protocols in Human Genetics, Suppl. 23 (1999), John Wiley & Sons, New York 12.9.1-12.9.16
15. Imperiale M.J., and Kochanek S. Adenovirus vectors: biology, design, and production. Curr. Top. Microbiol. Immunol. 273 (2004) 335-357
16. Jiang H., Pierce G.F., et al. Evidence of multiyear Factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe Hemophilia B. Mol. Ther. 14 3 (2006) 452-455
17. Kitajima K., Marchadier D.H.L., et al. Complete prevention of atherosclerosis in apoE-deficient mice by hepatic human apoE gene transfer with adeno-associated virus serotypes 7 and 8. Arterioscler. Throm. Vasc. Biol. 26 8 (2006) 1852-1857
18. Koeberl D.D., Sun B.D., et al. Early, sustained efficacy of adeno-associated virus vector-mediated gene therapy in glycogen storage disease type Ia. Gene Ther. 13 17 (2006) 1281-1289
19. Kolodka T.M., Finegold M., et al. Gene therapy for diabetes mellitus in rats by hepatic expression of insulin. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 3293-3297
20. Lee H.C., Kim J.-J., et al. Remission in models of type 1 diabetes by gene therapy using a single-chain insulin analogue. Nature 408 23 (2000) 483-488
21. Lipes M.A., Cooper E.M., et al. Insulin-secreting non-islet cells are resistant to autoimmune destruction. Proc. Natl. Acad. Sci. U.S.A. 93 16 (1996) 8595-8600
22. Manno C.S., Arruda V.R., et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 12 3 (2006) 342-347
23. McCarty D.M., Fu H., et al. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo self-complementary adeno-associated virus serotype 2 vector: global distribution and broad dispersion of AAV-mediated transgene expression in mouse brain. Gene Ther. 10 26 (2003) 2112-2118
24. Miao C.H., Nakai H., et al. Nonrandom transduction of recombinant adeno-associated virus vectors in mouse hepatocytes in vivo: cell cycling does not influence hepatocyte transduction. J. Virol. 74 8 (2000) 3793-3803
25. Nakai H., Herzog R.W., et al. Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX in mouse liver. Blood 91 12 (1998) 4600-4607
26. Nakai H., and Kay M. Looking into the safety of AAV vectors. Nature 424 (2003) 251
27. Nakai H., Montini E., et al. AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat. Genet. 34 3 (2003) 297-302
28. Nakai H., Storm T.A., et al. Recruitment of single-stranded recombinant adeno-associated virus vector genomes and intermolecular recombination are responsible for stable transduction of liver in vivo. J. Virol. 74 20 (2000) 9451-9463
29. Nakai H., Yant S.R., et al. Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J. Virol. 75 15 (2001) 6969-6976
30. Olson D., Paveglio S., et al. Glucose responsive hepatic insulin gene therapy of spontaneously diabetic BB/Wor rats. Hum. Gene Ther. 14 15 (2003) 1401-1413
31. Peng D., Qian C., et al. Transduction of hepatocellular carcinoma (HCC) using recombinant adeno-associated virus (rAAV): in vitro and in vivo effects of genotoxic agents. J. Hepatol. 32 6 (2000) 975-985
32. Porter M.H., Paveglio S.A., et al. Host cells reduce glucose uptake and glycogen deposition in response to hepatic insulin gene therapy. J. Invest. Med. 53 4 (2005) 201-212
33. Riu E., Mas A., et al. Counteraction of type 1 diabetic alterations by engineering skeletal muscle to produce insulin: insights from transgenic mice. Diabetes 51 3 (2002) 704-711
34. Sanlioglu S., Benson P., et al. Loss of ATM function enhances recombinant adeno-associated virus transduction and integration through pathways similar to UV irradiation. Virology 268 1 (2000) 68-78
35. Sanlioglu S., Duan D., et al. Two independent molecular pathways for recombinant adeno-associated virus genome conversion occur after UV-C and E4orf6 augmentation of transduction. Hum. Gene Ther. 10 4 (1999) 591-602
36. Sarkar R., Mucci M., et al. Long-term efficacy of adeno-associated virus serotypes 8 and 9 in Hemophilia A dogs and mice. Hum. Gene Ther. 17 4 (2006) 427-439
37. Simonson G.D., Groskreutz D.J., et al. Synthesis and processing of genetically modified human proinsulin by rat myoblast primary cultures. Hum. Gene Ther. 7 (1996) 71-78
38. Snyder R.O., Miao C., et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat. Med. 5 1 (1999) 64-70
39. Snyder R.O., Miao C.H., et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat. Genet. 16 (1997) 270-276
40. Song S., Embury J., et al. Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors. Gene Ther. 8 17 (2001) 1299-1306
41. Spergel J., Hsu W., et al. NF-IL-6, a member of the C/EBP family, regulates E1A-responsive promoters in the abscence of E1A. J. Virol. 66 2 (1992) 1021-1030
42. Spergel J.M., and Chen-Kiang S. Interleukin 6 enhances a cellular activity that functionally substitutes for E1A protein in transactivation. Proc. Natl. Acad. Sci. U.S.A. 88 15 (1991) 6472-6476
43. Thule P.M., Campbell A.G., et al. Hepatic insulin gene therapy prevents deterioration of vascular function and improves adipocytokine profile in STZ-diabetic rats 10.1152/ajpendo. 00134. 2005. Am. J. Physiol. Endocrinol. Metab. 290 1 (2006) E114-E122
44. Thule P.M., Liu J., et al. Glucose regulated production of human insulin in rat hepatocytes. Gene Ther. 7 3 (2000) 205-214
45. Thule P.M., and Liu J.M. Regulated hepatic insulin gene therapy of STZ-diabetic rats. Gene Ther. 7 20 (2000) 1744-1752
46. Wang X.S., Ponnazhagan S., et al. Rescue and replication signals of the adeno-associated virus 2 genome. J. Mol. Biol. 250 5 (1995) 573-580
47. Wang X.S., Ponnazhagan S., et al. Rescue and replication of adeno-associated virus type 2 as well as vector DNA sequences from recombinant plasmids containing deletions in the viral inverted terminal repeats: selective encapsidation of viral genomes in progeny virions. J. Virol. 70 3 (1996) 1668-1677
48. Wu Z., Asokan A., et al. Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes. J. Virol. 80 22 (2006) 11393-11397
49. Xiao W., Berta S.C., et al. Adeno-associated virus as a vector for liver-directed gene therapy. J. Virol. 72 12 (1998) 10222-10226
50. Yan Z., Zak R., et al. Ubiquitination of both adeno-associated virus type 2 and 5 capsid proteins affects the transduction efficiency of recombinant vectors. J. Virol. 76 5 (2002) 2043-2053
51. Yang Y., Nunes F.A., et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. U.S.A. 91 10 (1994) 4407-4411
52. Zhou S., Murphy J.M., et al. Adeno-associated virus-mediated delivery of erythropoietin leads to sustained elevation of hematocrit in nonhuman primates. Gene Ther. 5 (1998) 665-670